Literature DB >> 35714605

Innate-like T cells: A promising asset in anti-cancer immunity.

Martina Molgora1, Marco Colonna2.   

Abstract

In Nature, Chou et al. identify a subset of innate-like αβ T cells with high cytotoxic potential that accumulate in tumors and elicit an anti-tumor response. Given their capacity to maintain an activation state without undergoing exhaustion, these innate-like T cells may represent effective therapeutic agents for cell-based approaches.
Copyright © 2022. Published by Elsevier Inc.

Entities:  

Mesh：

Year:  2022        PMID： 35714605      PMCID： PMC9359000          DOI： 10.1016/j.ccell.2022.05.017

Source DB:  PubMed          Journal:  Cancer Cell        ISSN： 1535-6108            Impact factor:   38.585


  10 in total

Review 1.  Defining 'T cell exhaustion'.

Authors:  Christian U Blank; W Nicholas Haining; Werner Held; Patrick G Hogan; Axel Kallies; Enrico Lugli; Rachel C Lynn; Mary Philip; Anjana Rao; Nicholas P Restifo; Andrea Schietinger; Ton N Schumacher; Pamela L Schwartzberg; Arlene H Sharpe; Daniel E Speiser; E John Wherry; Benjamin A Youngblood; Dietmar Zehn
Journal:  Nat Rev Immunol       Date:  2019-09-30       Impact factor: 53.106

2.  Pan-cancer single-cell landscape of tumor-infiltrating T cells.

Authors:  Liangtao Zheng; Shishang Qin; Wen Si; Anqiang Wang; Baocai Xing; Ranran Gao; Xianwen Ren; Li Wang; Xiaojiang Wu; Ji Zhang; Nan Wu; Ning Zhang; Hong Zheng; Hanqiang Ouyang; Keyuan Chen; Zhaode Bu; Xueda Hu; Jiafu Ji; Zemin Zhang
Journal:  Science       Date:  2021-12-17       Impact factor: 63.714

3.  Programme of self-reactive innate-like T cell-mediated cancer immunity.

Authors:  Chun Chou; Xian Zhang; Chirag Krishna; Briana G Nixon; Saida Dadi; Kristelle J Capistrano; Emily R Kansler; Miranda Steele; Jian Han; Amy Shyu; Jing Zhang; Efstathios G Stamatiades; Ming Liu; Shun Li; Mytrang H Do; Chaucie Edwards; Davina S Kang; Chin-Tung Chen; Iris H Wei; Emmanouil P Pappou; Martin R Weiser; J Garcia-Aguilar; J Joshua Smith; Christina S Leslie; Ming O Li
Journal:  Nature       Date:  2022-04-20       Impact factor: 69.504

4.  Cancer Immunosurveillance by Tissue-Resident Innate Lymphoid Cells and Innate-like T Cells.

Authors:  Saïda Dadi; Sagar Chhangawala; Benjamin M Whitlock; Ruth A Franklin; Chong T Luo; Soyoung A Oh; Ahmed Toure; Yuri Pritykin; Morgan Huse; Christina S Leslie; Ming O Li
Journal:  Cell       Date:  2016-01-21       Impact factor: 41.582

Review 5.  Mucosal-associated invariant T cells and disease.

Authors:  Amine Toubal; Isabelle Nel; Sophie Lotersztajn; Agnès Lehuen
Journal:  Nat Rev Immunol       Date:  2019-10       Impact factor: 53.106

Review 6.  γδ T cells: pleiotropic immune effectors with therapeutic potential in cancer.

Authors:  Bruno Silva-Santos; Sofia Mensurado; Seth B Coffelt
Journal:  Nat Rev Cancer       Date:  2019-07       Impact factor: 60.716

Review 7.  Neoantigens in cancer immunotherapy.

Authors:  Ton N Schumacher; Robert D Schreiber
Journal:  Science       Date:  2015-04-03       Impact factor: 47.728

Review 8.  The Next Decade of Immune Checkpoint Therapy.

Authors:  Padmanee Sharma; Bilal A Siddiqui; Swetha Anandhan; Shalini S Yadav; Sumit K Subudhi; Jianjun Gao; Sangeeta Goswami; James P Allison
Journal:  Cancer Discov       Date:  2021-04       Impact factor: 39.397

9.  Neutrophils Driving Unconventional T Cells Mediate Resistance against Murine Sarcomas and Selected Human Tumors.

Authors:  Andrea Ponzetta; Roberta Carriero; Silvia Carnevale; Marialuisa Barbagallo; Martina Molgora; Chiara Perucchini; Elena Magrini; Francesca Gianni; Paolo Kunderfranco; Nadia Polentarutti; Fabio Pasqualini; Sabrina Di Marco; Domenico Supino; Clelia Peano; Ferdinando Cananzi; Piergiuseppe Colombo; Silvana Pilotti; Suliman Yousef Alomar; Eduardo Bonavita; Maria Rosaria Galdiero; Cecilia Garlanda; Alberto Mantovani; Sebastien Jaillon
Journal:  Cell       Date:  2019-06-27       Impact factor: 41.582

10.  Editorial: NKT Cells in Cancer Immunotherapy.

Authors:  Tonya J Webb; Weiming Yuan; Everett Meyer; Paolo Dellabona
Journal:  Front Immunol       Date:  2020-06-23       Impact factor: 7.561
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.